Current Therapeutic Approach to Acute Myocardial Infarction in Patients with Congenital Hemophilia.
Minerva Codruta BadescuManuela CiocoiuElena RezusOana Viola BadulescuDaniela Maria TănaseAnca OuatuNicoleta DimaAna Roxana Ganceanu-RusuDiana PopescuPetronela Nicoleta Seritean IsacTudor-Marcel GenesCiprian RezusPublished in: Life (Basel, Switzerland) (2021)
Advances in the treatment of hemophilia have made the life expectancy of hemophiliacs similar to that of the general population. Physicians have begun to face age-related diseases not previously encountered in individuals with hemophilia. Treatment of acute myocardial infarction (AMI) is particularly challenging because the therapeutic strategies influence both the patient's thrombotic and hemorrhagic risk. As progress has been made in the treatment of AMI over the last decade, we performed an in-depth analysis of the available literature, highlighting the latest advances in the therapy of AMI in hemophiliacs. It is generally accepted that after the optimal substitution therapy has been provided, patients with hemophilia should be treated in the same way as those in the general population. New-generation stents that allow short dual antiplatelet therapy and potent P2Y12 receptor inhibitors have begun to be successfully used. At a time when specific recommendations and relevant data are scarce, our study provides up-to-date information to physicians involved in the treatment of AMI in hemophiliacs.
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- antiplatelet therapy
- primary care
- systematic review
- healthcare
- acute coronary syndrome
- left ventricular
- stem cells
- heart failure
- mesenchymal stem cells
- machine learning
- coronary artery disease
- atrial fibrillation
- case report
- combination therapy
- deep learning